• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
RAC
Click for more information
2.11% $1.45

RACE ONCOLOGY LTD

Market Cap $282.0M  ! watchlist Created with Sketch. Add to my watchlist

Race Oncology Limited is an Australia-based clinical-stage biopharmaceutical company. The... Race Oncology Limited is an Australia-based clinical-stage biopharmaceutical company. The Company is focused on improving the lives of cancer patients around the world by developing a novel approach to both treating the cancer and protecting the heart. Its lead asset, bisantrene, is a small molecule chemotherapeutic. Bisantrene has a clinical history with demonstrated therapeutic benefits in both adult and pediatric patients, and compelling clinical data demonstrating an anticancer effect and less cardiotoxicity over certain anthracyclines, such as doxorubicin. It is advancing a reformulated bisantrene (RC220) to address the high unmet needs of patients across multiple oncology indications, with a clinical focus on anthracycline combinations. It is also exploring RC220 as a low intensity treatment for acute myeloid leukaemia.More

Corporate Spotlight

Race Oncology Ltd (RAC) is a specialty pharmaceutical company. Its business model is to pursue later stage drug assets, principally in the cancer field. Its important asset is a chemotherapy drug, called Bisantrene. Race Oncology is rediscovering Bisantrene.
View the full Corporate Spotlight arrow Created with Sketch.

director sees

Latest Threads

Tag Subject Date Created with Sketch. Comments Created with Sketch. Views Created with Sketch.
RAC
2019 SP
2
28/03/19 63 17K
28/03/19 Last post  EWexplorer Comments Created with Sketch.  63  Views Created with Sketch.  17K 
RAC
Ann: Race files Bisantrene IND with FDA 		26/03/19 7 1.3K
26/03/19 Last post  Hillyhawkie Comments Created with Sketch.  7  Views Created with Sketch.  1.3K 
RAC
RAC (ASX) Corporate Spotlight Updates 		25/03/19 3 783
25/03/19 Last post  Corporate Spotlight Comments Created with Sketch.  3  Views Created with Sketch.  783 
RAC
Ann: Appendix 3B 		13/03/19 1 560
13/03/19 Last post  mcexplorer Comments Created with Sketch.  1  Views Created with Sketch.  560 
RAC
Ann: Appendix 4D & Half-Year Financial Statements 		27/02/19 1 456
27/02/19 Last post  mcexplorer Comments Created with Sketch.  1  Views Created with Sketch.  456 
RAC
Ann: Principal Investigator appointed for Bisantrene 		25/02/19 4 1.5K
25/02/19 Last post  EWexplorer Comments Created with Sketch.  4  Views Created with Sketch.  1.5K 
RAC
Ann: Appendix 3Y-Dr William Garner 		14/02/19 0 277
14/02/19 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  277 
RAC
Ann: Change of Director's Interest Notice-Mr Chris Ntoumenopoulos 		12/02/19 1 567
12/02/19 Last post  mcexplorer Comments Created with Sketch.  1  Views Created with Sketch.  567 
RAC
Ann: Change of Director's Interest Notice-Mr Peter Molloy 		12/02/19 1 514
12/02/19 Last post  mcexplorer Comments Created with Sketch.  1  Views Created with Sketch.  514 
RAC
Ann: Change in substantial holding 		12/02/19 0 238
12/02/19 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  238 
RAC
Ann: Change of Director's Interest Notice-Dr William Garner 		12/02/19 0 201
12/02/19 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  201 
RAC
Ann: Race Receives $228k R&D Tax Incentive Refund 		08/02/19 3 976
08/02/19 Last post  EddyG Comments Created with Sketch.  3  Views Created with Sketch.  976 
RAC
Ann: Appendix 4C - quarterly 		31/01/19 2 3.1K
31/01/19 Last post  Infidel75 Comments Created with Sketch.  2  Views Created with Sketch.  3.1K 
RAC
Ann: Race appoints leading haematologist to support Bisantrene 		23/01/19 13 3.1K
23/01/19 Last post  mcexplorer Comments Created with Sketch.  13  Views Created with Sketch.  3.1K 
RAC
Ann: Appendix 3B 		22/01/19 0 282
22/01/19 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  282 
RAC
5 Million Shares bought by Insider 		15/01/19 21 7.0K
15/01/19 Last post  mcexplorer Comments Created with Sketch.  21  Views Created with Sketch.  7.0K 

See All Discussions arrow Created with Sketch.

Corporate Spotlight

(20min delay)
Last
$1.45 		Change
0.030(2.11%) 		Mkt cap ! $282.0M
Open High Low Value Volume
$1.43 $1.45 $1.40 $163.8K 115.3K

Buyers (Bids)

No. Vol. Price($)
1 500 $1.44
 

Sellers (Offers)

Price($) Vol. No.
$1.45 31396 1
View Market Depth
Last trade - 16.10pm 15/11/2024 (20 minute delay) ?
Last
$1.45 		  Change
0.030 ( 1.05 %)
Open High Low Volume
$1.43 $1.45 $1.40 11326
Last updated 15.59pm 15/11/2024 ?
RAC (ASX) Chart

Top Stories

Cyclone signs MOU with Vale for development of Iron Bear play

Cyclone Metals Lt has signed a Memorandum of Understanding with Vale S.A to support development of the former's iron ore project in Canada
Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado Blue Star Helium (ASX:BNL) has won approval from Colorado regulators to drill five fresh helium wells at its flagship.
To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels Put simply: if 3D Printing is a gold rush, Amaero is selling shovels. Or maybe it's more like sneakers in an arms race.
NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play Empire Energy (ASX:EEG) has confirmed the NT government has delivered environmental approvals for Carpentaria.
CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch CuFe Ltd (ASX:CUF) has decided not to wait around for Northern Star's Crossroads mine to get up and running, selling its $4M royalty right.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.